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Background: Previous studies have shown that single nucleotide polymorphisms (SNP) in IL28B and IL10R are
associated with sustained virological response (SVR) in chronic hepatitis C patients treated with pegilated interferon
plus ribavirin (P/R). The present study extends our earlier investigations on a large East-Central European cohort. The
allele frequencies of IL28B and IL10R in genotype 1 HCV infection were compared with that of healthy controls for
the purpose of examining the relationship between the polymorphisms and the SVR to P/R treatment.
Methods: A total of 748 chronic HCV1 infected patients (365 male, 383 female; 18–82 years) and 105 voluntary
blood donors as controls were enrolled. Four hundred and twenty HCV patients were treated with P/R for 24–72
weeks, out of them 195 (46.4%) achieved SVR. The IL28 rs12979860 SNP was determined using Custom Taqman
SNP Genotyping Assays. The IL10R −1087 (also known as IL10R −1082 (rs1800896) promoter region SNP was
determined by RT-PCR and restriction fragment length polymorphism analysis.
Results: The IL28B CC genotype occurred with lower frequency in HCV patients than in controls (26.1% vs 51.4%,
p<0.001). P/R treated patients with the IL28B CC genotype achieved higher SVR rate, as compared to patients with
CT (58.6% vs 40.8%, p=0.002). The prevalence of IL10R −1087 GG genotype was lower in patients than in controls
(31.8 % vs 52.2%, p<0.001). Among patients achieving SVR, the IL10R −1087 GG genotype occurred with higher
frequency than the AA (32.0% vs 17.4%, p=0.013). The IL28B T allele plus IL10R A allele combination was found with
higher prevalence in patients than in controls (52% vs 20.7%, p<0.001). The IL28B CC plus IL10R A allele
combination occurred with higher frequency among patients with SVR than in non-responders (21.3% vs 12.8%,
p=0.026). Both the IL28B CC plus IL10R GG and the IL28B CC plus IL10R A allele combinations occurred with lower
frequency in patients than in controls.
Conclusions: In our HCV1 patients, both the IL28B CC and IL10R GG genotypes are associated with clearance of
HCV. Moreover, distinct IL28B and IL10R allele combinations appear to be protective against chronic HCV1 infection
and predictors of response to P/R therapy.
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Hepatitis C virus (HCV) is a major global health problem:
currently 170 million subjects are suffering from HCV
infection worldwide [1,2]. The outcome of HCV infection
ranges from spontaneous viral clearance to hepatitis,
cirrhosis and hepatocellular carcinoma. Some individuals
have rapidly progressive liver disease, while others remain
symptom-free virus carriers. The exact causes of the differ-
ent disease courses are not known. Immune mechanisms,
as well as environmental factors are responsible for
the various HCV-related events [3]. As genetic factors
controlling the host immune response play a pivotal
role in HCV infection, a genetic predisposition may also
be crucial [4-6]. Cytokines are among the predominant
mechanisms of host defense against infection; they induce
inflammatory response that often leads to tissue injury,
but also serve as antiviral effectors. Moreover, cytokine
synthesis capacity has a significant genetic component.
This explains why differences exist between individuals in
their ability to produce cytokines, a fact which may also
be due to single-nucleotide polymorphisms (SNPs) within
the coding regions of cytokine genes. Cytokine genes are
polymorphic and certain SNPs modify the cytokine
production and affect the host immune response. In
HCV infection, secretion of an inappropriate amount of
cytokines may be associated with chronicity or resistance
to interferon (IFN) treatment [7].
The interleukin-28B (IL-28B) – also referred to as
interferonλ-3 (IFNλ-3) [8-12] – was shown to be
involved in the control of HCV infection. The genetic
polymorphisms of the encoding IL28B gene region deter-
mine the spontaneous and treatment induced clearance of
genotype 1 HCV (HCV1) [13-15].
IL-28B is expressed by peripheral blood mononuclear
cells, dendritic cells, and hepatocytes upon infection
with viruses or stimulation with double-stranded RNA.
IL28B in turn activates signal transduction through the
JAK-STAT pathway, exerts antiviral activity and has an
impact on natural clearance of HCV. IL-28B exhibits
fewer IFN-like adverse effects because IL-28B receptors are
expressed on a limited number of cell types. The receptor
for IL-28 is composed of a unique IL-28R-α chain that pairs
with the IL-10R-β chain [10,11]. IL28B gene on human
chromosome 19q was discovered using genomic screening
process in which the entire human genome was scanned
for putative functional variants [8,9].
Ge et al. [12] identified first a SNP (rs12979860) located
only 3 kilobases upstream from the IL28B gene, that
encodes IL-28B. They applied genome-wide association
study (GWAS), retrospectively analysed samples of 1,137
HCV infected individuals participating in a clinical trial
with pegylated interferon plus ribavirin (P/R) therapy, and
found that the high IL-28B production CC genotype was
associated with approximately a threefold greater rate ofSVR to P/R when compared with the TT genotype. This
finding was confirmed by others [13,14]. At the same
time it was also shown that the frequency of the CC
genotype was significantly lower in HCV patients
when compared to matched controls; thus, suggesting
that this variant may be linked to a higher rate of
natural clearance of HCV. This hypothesis was soon
strengthened by Thomas et al., who reported that the
IL28B CC genotype enhanced the spontaneous reso-
lution rate of HCV infection [15]. Thus, it became evident
that HCV patients who harbor the CC genotype at
rs12979860 are more prone to respond to P/R treatment
and to clear the virus than patients who do not possess
this genetic polymorphism.
The standard of care (SOC) treatment for HCV infection
is peginterferon plus ribavirin (P/R) therapy of 24–72 month
duration, depending on HCV genotype, pre-treatment viral
load and viral kinetic. This type of treatment may result in
sustained virological response (undetectable HCV RNA
after 24 weeks of the end of therapy) in approximately
40–45% of patients infected by genotype 1 HCV (HCV1)
the most common genotype in Europe. In the past 2 years,
new compounds, “direct acting antivirals” (DAAs) have also
been developed such as HCV protease- and polymerase
inhibitors, that significantly enhance SVR compared
with SOC even to 68–74% in treatment-naïve HCV1
individuals [16].
Since there are conflicting data on the role of the
regulatory Th2 cytokine interleukin-10 (IL-10) in HCV
infection [17-20], the polymorphism of the IL10R
gene has also been examined. In our preliminary studies,
the first from an East-Central European country, we
reported that not only IL28B but also IL10R −1087
(also known as IL10R-1082) genetic variants may play
a role in HCV infection [21,22].
Interleukin-10 (IL-10), produced by monocytes,
macrophages and T cells, inhibits both the activation
of CD4+ T-helper cells and the function of cytotoxic
CD8 + T, NK and antigen-presenting cells, and also
modulates hepatic stellate cell collagen synthesis. IL-10
plays a regulatory role in immune reaction and suppresses
inflammatory responses by inhibiting the production of
pro-inflammatory cytokines. Its effect is mediated through
the IL-10 receptor (IL-10R), which is a heterodimer
that consists of both IL-10R1 required for binding,
and IL-10R2 required for signaling. Increased IL-10
production was reported in association with the -1082G,
-819C, -592GCC IL-10 promoter (ATA) haplotype [23,24].
If macrophages secrete large amount of IL-10, it may
decrease circulating TFN-α and IL-6 levels, thus, reducing
their harmful effects. A higher frequency of IL10 -1082 GG
genotype was found in older healthy controls than in
patients with myocardiac infarction; high IL-10 production
was protective for longevity [25].
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on a large East-Central European cohort in Hungary. The
allele frequencies of IL28B and IL10R −1087 in HCV1
infection were compared with that of healthy controls for
the purpose of examining the relationship between the
polymorphisms and the response to PEG-IFN and ribavirin
(P/R) treatment. We find that in HCV1-infected
East-Central European patients, both the IL28B CC and
IL10R GG genotypes are associated with clearance of HCV.
Moreover, distinct IL28B and IL10R allele combinations
appear to be protective against chronic HCV1 infection
and predictors of response to P/R therapy.
Methods
Ethics
This work has been carried out in accordance with the
guidelines of the 1975 Declaration of Helsinki and has
been approved by both the National Ethics Committee
(ETT TUKEB Budapest, No 490/010) and the Regional
Ethics Committee at the University of Pécs.
All the patients agreed to participate in the study, and
provided written informed consent.
Patients
A total of 748 HCV1 infected patients (365 men, 383 female,
ranging in age from 18 to 82 years, mean 54 ± 10 years)
were enrolled. All subjects were inpatients in 10 Hungarian
city hospitals or university clinics between January 2007
and December 2009.
The diagnosis of chronic hepatitis C was based on
persistent elevation of serum alanine aminotransferase
(ALT) levels >6 months in the presence of anti-HCV by
ELISA and HCV RNA by real-time reverse transcriptase-
polymerase chain reaction (RT-PCR). Quantitation of
plasma HCV RNA was carried out using Cobas Amplicor
2.0 (Hoffmann-La Roche Inc.). HCV genotype was deter-
mined by a genotype specific probe based assay in the 5′
untranslated region (LiPA; Innogentics, Ghent, Belgium).
(In Hungary, >95% of HCV patients have been infected
with HCV genotype 1. In Eastern European countries the
prevalence of genotype 1 ranges between 57% and 99%
[26]). In 70% of our patients percutaneous liver biopsy
was performed.
Of the 748 HCV1 patients, 420 were treated with pegy-
lated interferon alfa 2a/2b (Pegasys, Hoffmann-La Roche
Inc./Pegintron, SP Labo N.V. Belgium) 135–180 μg/1.0-
1.5 μg/kg subcutaneously per week, and ribavirin (Copegus,
Hoffmann-La Roche Inc./Rebetol, SP Labo N.V. Belgium)
1000–1200 mg orally per day for 24–72 weeks, then
followed up for 24 weeks.
Subjects who had undetectable HCV RNA levels
following 24 weeks of therapy were designated as sustained
virological response (SVR), undetectable serum HCV RNA
at week 4 after starting treatment as rapid virologicalresponse (RVR), undetectable HCV RNA at week 12 after
starting therapy as early virological response (EVR). In our
paper, patients who did not achieve SVR were regarded as
“non-responders” (non-SVR).
One hundred and five healthy individuals (64 men, 41
female, mean age 45 ± 3 years), who were consecutive
voluntary blood donors with normal liver function tests
and negative for HBV, HCV and HIV serology, served as
controls.
Genotyping
DNA was isolated from peripheral blood by a standard
desalting method. The IL28B rs12979860 SNP was
determined using Custom Taqman SNP Genotyping
Assays (Applied Biosystems, Life Technologies, Foster, CA,
USA). The IL10R −1087 (also known as IL10R −1082)
(rs1800896) promoter region was required for the formation
of the EcoNI recognition sequence 5′-AAGACAACAC
TACTAAGGCT-3′; the lower primer was 5′-TAAA
TATCCTCAAAGTTCC-3′. After cutting the amplified
product (584 bp) by EcoNI, homozygote GG was identified
by two fragments 315 and 279 bp, while heterozygote AG
had 310, 280, 252 and 28 bp fragments and homozygote
AA had 310, 252 and 28 bp fragments [27].
Statistical analysis
Statistical analysis was carried out using the SPSS 16.0
for Windows (SPSS Inc., Chicago, IL, USA). The allele
and genotype frequencies were compared with Pearson’s
χ2 test. Binary logistic regression analysis was performed to
observe the individual contributions of the polymorphisms.
A p value of <0.05 was considered significant.
Results
Of 420 peginterferon and ribavirin (P/R) treated patients
195 (46.4%) achieved SVR. Patients with RVR (20% of
treated) achieved a 86% SVR rate, while those with EVR
(55% of treated) showed a 65% SVR rate.
As shown in Table 1, when comparing the IL28B
genotype frequencies between groups of healthy controls
and patients, the CC genotype occurred with lower
frequency in HCV patients than in controls, thus,
suggesting its protective effect against chronic hepatitits C.
On the other hand, CT heterozygosity and T alleles were
more prevalent in patients, and may, therefore, convey
susceptibility for the disease.
As shown in Table 2, subjects that received P/R therapy
and who had the IL28B CC genotype achieved higher rates
of SVR than subjects who had CT genotype (58.6% vs
40.8%) (OR 2.057, 95% CI: 1.305-3.058, p = 0.002), or those
carrying the T allele (41.8%, OR 1.976, 95% CI: 1.263-3.058,
p = 0.002).
As shown in Table 3, IL10R GG genotype occurred
with lower frequency in patients (31.8%) than in controls
Table 1 Prevalence of IL28B genotypes in Hungarian HCV






CC 195 (26.1%) 54 (51.4%) 0.333 (0.22 - 0.505)
P < 0.001
CT 411 (54.9%) 39 (37.1%) 2.064 (1.354 - 3.145)
p = 0.001
C allele 606 (81.02%) 93 (88.6%) 0.551 (0.294-1.032)
p = 0.059
TT 142 (19.0%) 12 (11.4%) 1.816 (0.969 – 3.404)
p = 0.059
T allele (non-CC) 553 (73.9%) 51 (48.6%) 3.003 (1.981 – 4.552)
P < 0.001
Table 3 Prevalence of IL10R −1087 genotypes in HCV








GG 214 (31.8) 48 (52.2%) 0.428 (0.276 - 0.665)
p < 0.001
GA 333 (49.6%) 32 (34.8%) 1.842 (1.169 – 2.903)
p = 0.008
G allele 547 (81.4%) 80 (87.0%) 0.656 (0.347-1.241)
p = 0.192
AA 125 (18.6%) 12 (13.0%) 1.523 (0.806 – 2.881)
p = 0.192
A allele (non-GG) 458 (68.15%) 44 (47.8%) 2.335 (1.504 – 3.625)
p < 0.001
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AA allele was 68.15% in patients and 47.8% in healthy
individuals (OR: 2.335, p < 0.001).
Among P/R treated patients with SVR, the IL10R GG
genotype occurred with higher frequency than the AA
genotype, (57/178, 32.0% vs 31/178, 17.4%, (OR: 1.84,
95% CI 1.13-2.98, p = 0.013).
The SVR rate in patients with IL10R GG genotype was
42.2% (59/125); in those with GA 47.4% (88/178) and in
AA patients 39.7% (31/78). HCV patients with A allele
(non-GG genotype) achieved SVR in 46.4% (119/256).Genotype combinations
Healthy controls and HCV1 patients
The prevalence of the double wild type combination
of the IL28B CC plus IL10R GG was lower (9.2%) in
HCV patients than in healthy controls (23.9%) (OR 0.322,
p < 0.001).
The IL28B CC plus IL10R A allele combination
likewise occurred with lower frequency in patients
(16.1%) when compared with controls (27.2,%, OR 0.515,
p = 0.009). Both combinations suggest a protective effect
against chronic HCV infection.
The prevalence of IL28B T allele plus IL10R A allele
combination was higher in patients (52.4%) than in healthyTable 2 Sustained virological response (SVR) rate
stratified by IL28B genotypes in Hungarian HCV patients
Treated SVR
IL28B genotype n Number of patients Percentage
CC 116 68 58.6%
CT 228 93 40.8%
TT 76 34 44. 7%
T allele (non-CC) 304 127 41.8%controls (20.7%), thus, leading to a more than fourfold risk
increase of the disease (OR 4.231, p < 0.001) (Table 4).
Comparison of subjects with sustained virologic response
(SVR) versus non-responder (non-SVR) patients
The IL28B CC plus IL10R −1087 AA allele combination
was found with higher frequency among patients achieving
SVR (21.3%), than in non-responders (12.8%, OR 1.848,
95% CI 1.070-3.190, p = 0.026). In patients with SVR, the
prevalence of the IL28B CC plus IL10R GG combination
was 12.4%, whereas in non-responders it was 7.9%
(OR 1.648, NS) (Table 4).
Cumulatively, the data suggest that SNPs in both IL28B
and the IL-10 promoter region, and specific combinations
thereof, are associated with protection against HCV infection
and differential responsiveness to IFN therapy.
Discussion
Previous studies have shown that IL28B SNP at the poly-
morphic site rs129798060 with the CC genotype, and IL10
receptor SNP at −1082 with the G allele are associated with
susceptibility to chronic hepatitis C virus infection and
response to combined antiviral therapy [12-14,17,28,29]. In
our cohort of Hungarian patients, we evaluated these SNPs
in a total of 748 patients infected with genotype 1 HCV
from 10 centers throughout Hungary. To our knowledge,
this is largest study of its type on HCV-infected subjects
from East-Central Europe. Our results show that polymor-
phisms of both IL28B and IL10R genes play a role in the
outcome of chronic hepatitis C in a new cohort. We were
able to demonstrate that IL28B CC genotype is a strong
predictor of SVR in patients treated with P/R, and protects
against the disease. The current study on a large cohort
confirms the results of our earlier studies [21,22]. This gen-
etic variant of IL28B may be associated with an elevated
production of IL-28B (IFNλ-3) but this has not been found
in all studies [12].
Table 4 IL28B and IL10R −1087 genotype combinations in the different study groups
IL28B genotype
CC CC T allele T allele
IL10R genotype HCV n = 664 GG 61 (9.2%) OR:0.322 (0.186-0.556) 148 (22.3%) 0.728 (0.446-1.188)
A allele 107 (16.1%) p < 0.001 348 (52.4%) p = 0.202
Controls n = 92 GG 22 (23.9%) OR:0.515 (0.311-0.852) 26 (28.3%) OR:4.231 (2.497-7.169)
A allele 25 (27.2%) p = 0.009 19 (20.7%) p < 0.001
SVR n = 178 GG 22 (12.4%) OR:1.648 (0.837-3.247) 37 (20.8%) OR:0.803 (0.496-1.301)
A allele 38 (21.3%) p = 0.146 81 (45.6%) p = 0.372
Non-responders n = 203 GG 16 (7.9%) OR: 1.848 (1.070-3.190) 50 (24.6%) OR:0.692 (0.462-1.037)
A allele 26 (12.8%) p = 0.026 (54.7%)111 p = 0.074
Prevalence of IL28B CC plus IL10R GG in HCV patients vs. controls OR: 0.322.
IL28B CC plus IL10R A allele OR: 0.515.
IL28B T allele plus IL10R A allele OR: 4.231.
Prevalence of IL28B CC plus IL10R A allele in pts with SVR vs. non-responders OR:1.848.
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[12-14]. The frequency of IL28B CC in HCV1 patients
was lower than in healthy controls, this fact may mean
that individuals with IL28B CC genotype are protected
against chronic hepatitis C. Patients with IL28 CC geno-
type may have a high likelihood of SVR and possibly need
only the standard of care P/R treatment, particularly if
they have other positive predictors: low viral load, young
age, female, short duration of infection, absence of cirrho-
sis and low BMI. Under such circumstances, an IL28B CC
will not only predict SVR but also motivate both the pa-
tient and the doctor, serving to enhance adherence as well
However, it must be also emphasised that the strongest
positive predictor of SVR is not the IL28B CC, but the
RVR [30,31] as it was found in our cases too, when 86% of
patients with RVR eliminated their HCV1 infections.
The question arises whether HCV1 patients carrying
the IL28B TT genotype always require a more complex
(e.g. triple) therapy with direct acting antivirals (DAAs)?
It is conceivable that patients with the TT homozygosity,
who also have other negative predictors (such as previ-
ous non-response, high viral load, cirrhosis, obesity,
insulin resistance), will be candidates for treatment with
DAAs.
Recently, it was found that both the triple therapy
with DAAs, (e.g. protease inhibitors plus P/R) and the
IFN-free anti-HCV treatment may overcome the effect of
the unfavourable TT IL28B polymorphism. Thus, in the
future, the relevance of IL28B genotyping may become
limited in the individualized treatment for HCV1 infection
[32-35]. However, Bronowicki et al. reported that 100% of
treatment-naive HCV1 patients with IL28B CC achieved
SVR, even with 12 weeks of a protease inhibitor telaprevir
and P/R combination therapy [36]. Therefore, IL28B
genotyping may continue to be of importance in the
shortening of treatment duration.Thus, the findings of IL28B polymorphisms will allow
one to predict with better accuracy which patients are
likely to respond to the standard of care P/R therapy.
However, it must be stressed that the effect of the
favourable variant is not absolute: not all carriers of the
“good response genotype” clear the virus; nor do all patients
lacking it fail to benefit from the P/R treatment [30,31].
It was noted previously that IL10 -1082 GG genotype
was frequent in HCV, when mononuclear cells produced
two-fold greater quantities of IL-10 compared with patients
with IL10 AA genotype [25,26]. Vigidal et al. reported, that
IL10 gene promoter −1082 GG genotype occurred more
frequently in HCV patients than in controls and that the
GG homozygosity was associated with poor response to
IFN. This genotype was identified in 34.6% of 80
HCV patients compared with 6/33 (16.7%) of controls
(p = 0.048). However, this study focused on limited numbers
of both patients and control subjects [28]. Meta-analysis of
Zhang et al., also showed that the IL10 -1082 GG genotype
was associated with susceptibility for chronic HCV infection
[29]. Yet, Afzal et al. reported that the frequency of −1082
GA genotype was higher in healthy individuals than in
HCV patients, suggesting the protective effect of this
variant [19]. Lio et al. noted that the IL10 -1082 GG
was associated with spontaneous recovery from HCV
infection [18], while according to Gao et al. -1082 AA
conferred an increased risk of persistent HCV infection
[37]. Knapp et al. found that HCV patients with SVR
showed higher frequency of IL10 -1082 GG genotype
than non-responders (26.9% vs 14.0% OR 2.28, 95%
CI 1.21-4.32, p = 0.05) [17].
In this study we investigated the IL10R promoter gene
polymorphisms at position −1087 relative to transcription
start site and proved that the −1087 GG occurs at a lower
frequency in HCV patients as compared with controls;
thus, this variant may be protective against the disease. At
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was higher in the patients’ group - as a potential genetic
marker of susceptibility to the HCV1 infection. In patients
who achieved SVR, the IL10R GG genotype occurred with
higher (32.%) frequency than AA (17.4%), and the IL28B
CC plus IL10R −1087 A allele combination was also found
with higher rate among patients achieving SVR (21.3%),
than in non-responders (12.8%).
Our findings on the role of IL10R gene polymorphism
in HCV1 infection are rather conflicting, and may
contradict both some of the previously published data
[28,29] as well as the known biological effect of IL-10.
The reasons for these discrepancies are not clear. The
study populations may differ with regard to factors that
influence SVR: viral load, obesity, fibrosis, ethnicity and
sex. Additional studies are required to define the roles of
these factors in connection with IL10 polymorphisms in
chronic hepatitis C.
Conclusions
We demonstrated that not only IL28B CC but also
IL10R GG genotype and certain IL28B plus IL10R
allele combinations may be protective genetic variants
in Hungarian patients with chronic HCV1 infection.
By predicting which persons are most likely to respond to
IFN-based therapy, the examination of these polymorphisms
may help to manage an individualized approach to treat
HCV patients. Genotyping both IL28B and IL10R may
offer a baseline screening test, that, however, should be
combined with other well-known pre- and on-treatment
predictors for the outcome of the disease and choosing
the most appropriate type of anti-HCV therapy. In the era
of DAAs for the treatment of HCV infection, the prognos-
tic role of these genetic tests may be of less importance.
Yet, in certain circumstances, the IL28B genotyping can
be useful; e.g. in the shortening of treatment duration
in P/R plus DAA-treated HCV patients. It is evident,
however, that as an on-treatment predictor, rapid viro-
logical response remains the strongest prognostic factor,
even across IL28B genotypes [38].
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